Haloperidol dose for the acute phase of schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Donnelly, Lorna ^a   Rathbone, John ^b   Adams, Clive E ^c  

^a NHS LOTHIAN   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; HALOPERIDOL; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGITATION; AKATHISIA; BEHAVIOR; BLURRED VISION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSKINESIA; DYSTONIC DISORDER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; ORTHOSTATIC HYPOTENSION; PATIENT DROPOUT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEDATION; SIMPSON-ANGUS SCALE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; ACUTE DISEASE; META ANALYSIS;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; HALOPERIDOL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84893409391     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001951.pub2     Document Type: Review

References (174)

1. Curtis CE, Mann M, Piscani K, Burr G, Hitzemann RJ, Hirschowitz J. A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami. 1995.
2. Donlon PT, Hopkin JT, Tupin JP, Wicks JJ, Wahba M, Meadow A. Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. Archives of General Psychiatry 1980;6:691-5.
3. Wahba M, Donlon PT, Meadow A. Cognitive changes in acute schizophrenia with brief neuroleptic treatment. American Journal of Psychiatry 1981;138(10):1307-10.
4. Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM. A two-phase, double-blind randomised study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta Psychiatrica Scandinavica 1997;4:343-50.
5. Javaid JI, Janicak PG, Hedeker D, Sharma RP, Davis JM. Steady-state plasma level prediction for haloperidol from a single test dose. Psychopharmacology Bulletin 1991;27(1):83-8.
6. Javaid JI, Janicak PG, Sharma RP, Leach AM, Davis JM, Wang Z. Prediction of haloperidol steady-state levels in plasma after a single test dose. Journal of Clinical Psychopharmacology 1996;16(1):45-50.
7. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 2000;4:514-20.
8. Khanna A, Lal N, Dalal PK, Khalid A, Trivedi JK. Treatment of acute and transient psychotic disorders with low and high doses of oral haloperidol. Indian Journal of Psychiatry 1997;39(2):136-42.
9. Klieser E, Lehmann E. Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol. Neuropsychobiology 1987;18(3):122-6.
10. Klieser E, Lehmann E. Experimental comparison of the efficacy of standardized haloperidol treatment and adequate individual dosages in acute schizophrenic states. Fortschritte der Neurologie Psychiatrie 1992;3:126-9.
11. Liang S. Comparison of therapeutic effects between haloperidol and insulin coma for schizophrenia and the optimal blood level of haloperidol. Chinese Journal of Neurology and Psychiatry 1987;20(1):43-8.
12. Louza Neto MR, Muller Spahn F, Ruther E, Scherer J. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry 1988;21(5):226-31. [MEDLINE: 3227054]
13. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold. Archives of General Psychiatry 1991;48(8):739-45.
14. McEvoy JP, Schooler NR, Wilson WH. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin 1991;27(2):97-101.
15. Modestin J, Toffler G, Pia M, Greub E. Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens. Pharmacopsychiatria 1983;16:4121-6.
16. Neborsky R, Depry D, Janowsky DS, Munson E, Perel J. Haloperidol plasma red blood-cell ratios and clinical efficacy. Psychopharmacology Bulletin 1982;18(4):17-20.
17. Neborsky R, Janowsky D, Munson E, Depry D. Rapid treatment of acute psychotic symptoms with high-and low-dose haloperidol. Behavioral considerations. Archives of General Psychiatry 1981;38(2):195-9.
18. Neborsky R, Janowsky D, Munson E, Hornbeck C, Depry D. Behavioral prediction of response to haloperidol: a test dose strategy. Journal of Clinical Psychiatry 1982;43(4):157-8.
19. Neborsky RJ, Janowsky DS, Perel JM. Red-blood-cell plasma haloperidol ratios and antipsychotic efficacy. Psychiatry Research 1982;6(1):123-4.
20. Neborsky RJ, Janowsky DS, Perel JM, Munson E, Depry D. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry 1984;45(1):10-3.
21. Oosthuizen P, Emsley R, Turner HJ, Keyter N. A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. International Journal of Neuropsychopharmacology 2004;7(2):125-31. [MEDLINE: 15003147]
22. Palao DJ, Arauxo A, Brunet M, Bernardo M, Haro JM, Ferrer J, et al. Haloperidol: therapeutic window in schizophrenia. Journal of Clinical Psychopharmacology 1994;14(5):303-10.
23. Palao DJ, Arauxo A, Brunet M, Marquez M, Bernardo M, Ferrer J, et al. Positive versus negative symptoms in schizophrenia: response to haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1994;18(1):155-64.
24. Palao DJ, Arauxo A, Haro JM, Brunet M, Bernardo M, Volavka J, et al. The relationship between plasma haloperidol concentrations and clinical results. Archives of General Psychiatry 1996;53(12):1167-9.
25. Doddi S, Rifkin A, Karajgi B, Cooper T, Borenstein M. Blood levels of haloperidol and clinical outcome in schizophrenia. Journal of Clinical Psychopharmacology 1994;14(3):187-95.
26. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M. Dosage of haloperidol for schizophrenia. Archives of General Psychiatry 1991;48(2):166-70.
27. Simpson GM, Angus JWS, Edwards JG. A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research 1967;9(8):401-12.
28. Garver DL, Steinberg JL, McDermott BE, Yao JK, Ramberg JE, Lewis S, et al. Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?. Neuropsychopharmacology 1997;16(3):191-201.
29. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J. Further evidence of a dose-response threshold for haloperidol in psychosis. American Journal of Psychiatry 1995;152(8):1210-12.
30. Bitter I, Volavka J, Cooper J, Scheurer ZJ, Camus L, Bakall R. Haloperidol blood levels and clinical effects in schizophrenia. Proceedings of the 8th World Congress of Psychiatry; 1989 Oct 13-19; Athens, Greece. 1989.
31. Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research 1998;81(1):51-5.
32. Convit A, Volavka J, Czobor P, De Asis J, Evangelista C. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. American Journal of Psychiatry 1994;151(1):49-56.
33. Cooper TB, Volavka J, Czobor P. Plasma drug level and clinical response. Journal of Clinical Psychopharmacology 1992;12(2):134-6.
34. Czobor P, Volavka J. Dimensions of the brief psychiatric rating scale: an examination of stability during haloperidol treatment. Comprehensive Psychiatry 1996;37(3):205-15.
35. Czobor P, Volavka J. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Research 1992;42(2):129-44.
36. Czobor P, Volavka J. Positive and negative symptoms: is their change related?. Schizophrenia Bulletin 1996;22(4):577-90.
37. Czobor P, Volavka J. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. Journal of Clinical Psychopharmacology 1993;13(5):332-42.
38. Krakowski M, Czobor P, Volavka J. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Research 1997;71(1):19-26.
39. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, et al. Haloperidol blood levels and clinical effects. Archives of General Psychiatry 1992;5:354-61.
40. Volavka J, Cooper TB, Meisner M, Bitter I, Czobor P, Jaeger J. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Psychopharmacology Bulletin 1990;26(1):13-7.
41. Volavka J, Douyon R, Convit A, Czobor P, Cooper TB. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited. Archives of General Psychiatry 1992;49(12):999-1000. [MEDLINE: 1449388]
42. Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research 1998;81(1):51-5.
43. Czobor P, Volavka J. Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. Comprehensive Psychiatry 1996;37(3):205-15.
44. Czobor P, Volavka J. Positive and negative symptoms: is their change related?. Schizophrenia Bulletin 1996;22(4):577-90.
45. Volavka J, Cooper TB, Czobor P, Meisner M. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. Psychopharmacology Bulletin 1996;32(1):75-9.
46. Volavka J, Cooper TB, Czobor P, Meisner M. Haloperidol plasma levels and clinical effects. Psychopharmacology Bulletin 1995;31:536.
47. Volavka J, Cooper TB, Czobor P, Meisner M. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry 1995;52(10):837-45.
48. Lehmann E, Lienert GA. Differential improvements from haloperidol in two types of schizophrenics. Psychopharmacology 1984;84(1):96-7.
49. Winter M, Lehmann E, Scholz OB. Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder. Neuropsychobiology 1984;2-3:115-21.
50. Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH, et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 1980;67(1):17-23.
51. Boyer P, Puech AJ. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique ses neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie 1987;2(4):296-305.
52. Coryell W, Kelly M, Perry PJ, Miller DD. Haloperidol plasma levels and acute clinical change in schizophrenia. Journal of Clinical Psychopharmacology 1990;10(6):397-402.
53. Kelly MW, Perry PJ, Coryell WH, Miller DD, Arndt SV. Reduced haloperidol plasma-concentration and clinical-response in acute exacerbations of schizophrenia. Psychopharmacology 1990;102(4):514-20.
54. Coryell W, Miller DD, Perry PJ. Haloperidol plasma levels and dose optimization. American Journal of Psychiatry 1998;155(1):48-53.
55. Coryell WH, Miller DD, Perry PJ. The clinical utility of haloperidol plasma levels. Schizophrenia Research 1995;15(1-2):146.
56. Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, et al. Blood levels of haloperidol and clinical response. Psychopharmacology Bulletin 1985;21(1):48-51.
57. Ericksen SE, Hurt SW, Chang S. Haloperidol dose, plasma levels, and clinical response: a double-blind study. Psychopharmacology Bulletin 1978;14(2):15-6.
58. Hurt SW, Holzma PS, Davis JM. Thought disorder. The measurement of its changes. Archives of General Psychiatry 1983;40:1281-5.
59. Dubin WR, Waxman HM, Weiss KJ, Ramchandani D, Tavani-Petrone C. Rapid tranquilization: the efficacy of oral concentrate. Journal of Clinical Psychiatry 1985;46(11):475-8.
60. Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, et al. Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses [Activite cetone reductase erythrocytaire, taux plasmatiques d'haloperidol et psychoses aigues]. Encephale 1995;21(6):417-24.
61. Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychological Medicine 1988;18:873-85.
62. Mavroidis ML, Garver DL, Kanter DR, Hirschowitz J. Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacology Bulletin 1985;21(1):62-5. [MEDLINE: 3983340]
63. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 1983;81(4):354-6.
64. Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML. Haloperidol plasma and red blood cell levels and clinical antipsychotic response. Journal of Clinical Psychopharmacology 1984;4(3):133-7.
65. Gerlach J, Behnke K, Heltberg J, Munk-Andersen E., Nielsen H. Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross-over study of therapeutic effectiveness, side effects and plasma concentrations [Le dogmatil et l'haloperidol dans le traitement de la schizophrenie. Etude croisee en double aveugle de l'action therapeutique, des effets secondaires et des concentrations plasmatiques]. Semaine des Hopitaux 1985;61(19):1309-16.
66. Hirschowitz J, Hitzemann R, Piscani K, Burr G, Frecska E, Culliton D, et al. The Dose Reduction in Schizophrenia (DORIS) Study: a final report. Schizophrenia Research 1997;23(1):31-43.
67. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996;15(5):429-36.
68. Ortega-Soto HA, Fernandez AE, Pinedo H, De La Torre P, Brunner E, Apiquian R. Clinical trial of haloperidol threshold doses. Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-27; San Francisco. 1993.
69. Ortega-Soto HA, Brunner E, Apiquian R, De La Torre P. Therapeutic minimum dose of haloperidol in schizophrenia. Neuropsychopharmocology 1994;10(3S Pt 2):140S.
70. Ortega-Soto HA, Fernandez AE, Pinedo H, De La Torre P, Brunner E, Apiquian R. Clinical trial of haloperidol threshold doses. Patient Care for the 21st Century: Asserting Professional Values with Economic Restraints. Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993, May 22-27; San Francisco. 1993.
71. Reschke RW. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Diseases of the Nervous System 1974;35(3):112-5. [MEDLINE: 17894080]
72. Santos JL, Cabranes JA, Almoguera I, Ramos JA, Vazquez C, Angeles F. Clinical implications of determination of plasma haloperidol levels. Acta Psychiatrica Scandinavica 1989;79(4):348-54.
73. Santos JL, Cabranes JA, Vazquez C, Fuentenebro F, Almoguera I, Ramos JA. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia. Biological Psychiatry 1989;26(4):381-8.
74. Santos JL, Ramos JA, Prieto P, Almoguera I, Vazquez C, Rubio ME, et al. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia-clinical utility. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1989;13(6):917-25.
75. Sim CB, Lee YC, Hwang JP. Haloperidol for schizophrenic inpatients with three doseage regimens. Psychiatry Today: Accomplishments and Promises; Proceedings of the 8th World Congress of Psychiatry; 1989, Oct 12-19; Athens, Greece. London: Excerpta Medica International Congress Series 899, 1989:817.
76. Smith RC. Plasma haloperidol levels-clinical-response and fancy mathematics - reply. Archives of General Psychiatry 1985;42(8):835-8.
77. Smith RC. The interpretation of plasma haloperidol concentrations-reply. Archives of General Psychiatry 1985;42(8):839-40.
78. Smith RC, Baumgartner R, Burd A, Calderon M, Largen J, Mauldin M, et al. Cortical atrophy and white matter density in the brains of schizophrenics and clinical-response to neuroleptics. Acta Psychiatrica Scandinavica 1987;75(1):11-9.
79. Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, et al. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Archives of General Psychiatry 1984;41(11):1044-9.
80. Smith RC, Burd A, Baumgartner R, Ravichandran GK, Mauldin M. Haloperidol and thioridazine drug levels and clinical-response in schizophrenia-comparison of gas-liquid-chromatography and radioreceptor drug level assays. Psychopharmacology Bulletin 1985;21(1):52-8.
81. Smith RC, Ravichandran GK, Vroulis G, Mauldin M, Baumgartner R, Gordon J, et al. Lateral ventricular enlargement and clinical-response in schizophrenia. Psychiatry Research 1985;14(3):241-53.
82. Smith RC, Shvartsburd A, Vroulis G, Ravichandran GK, Mauldin M, Baumgartner R. Comparative efficacy of red-cell and plasma haloperidol as predictors of clinical-response in schizophrenia. Psychopharmacology 1985;85(4):449-55.
83. Smith RC. Plasma haloperidol levels and clinical response. Archives of General Psychiatry 1987;44(12):1110-2.
84. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry 1990;47(8):754-8.
85. Volavka J, Cooper TB, Czobor P, Lindenmayer J P, Citrome LL, Mohr P, et al. High dose treatment with haloperidol: the effect of dose reduction. Journal of Clinical Psychopharmacology 2000;20(2):252-6. [MEDLINE: 10770466]
86. Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P. Haloperidol blood levels and effects in schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego. 1997.
87. Baker R, Mack R, Morris D, Sebree T, Kashkin KB. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam, Netherlands. 1996.
88. Bark N, Mack R, Zborowski J, Morris D, Sebree T, Shook S, et al. Efficacy and safety of three doses of sertindole and haloperidol in schizophrenic patients. Biological Psychiatry 1996;39:597.
89. Larson GL, Mack RJ, Zborowski J, Morris DD, Sebree TB, Wallin BA. Three doses each of sertindole and haloperidol in schizophrenics. Proceedings of the 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain. 1996.
90. Tamminga C, Mack R, Zborowski J, Morris D, Sebree T, Wallin B. Efficacy and safety of three doses of sertindole and haldol in schizophrenic patients. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996.
91. ZimbroffDL, Kane JM, Tamminga C, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997;154(6):782-91.
92. ZimbroffDL, Mack RJ, Morris DD, Silber CJ. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Schizophrenia 1996: Breaking Down the Barriers. Proceedings of the 4th International Conference; 1996 Oct 6-9; Vancouver. 1996.
93. ZimbroffDL, Mack RJ, Zborowski JN, Morris DD, Sebree TB, Wallin BA. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York. 1996.
94. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophrenia Research 1990;3:247-51.
95. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
96. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 1997;154 Suppl 4:1-63.
97. Awad AG. Methodological and design issues in clinical trials of new neuroleptics: an overview. British Journal of Psychiatry 1993;Suppl 22:51-7.
98. Awad AG, Voruganti LP. Cost-utility analysis in schizophrenia. Journal of Clinical Psychiatry 1999;60 Suppl 3:22-6.
99. Bagnall, A-M. Lewis, RA. Leitner, ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI:]
100. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry 1984;141(6):748-52.
101. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Archives of General Psychiatry 1988;45:79-91.
102. Baldessarini RJ, Kando JC, Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. American Journal of Psychiatry 1995;152(7):1038-44.
103. Bezchlibnyk-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Canadian Journal of Psychiatry 1994;39(2):74-84.
104. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
105. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
106. Bollini P, Pampallona S, Orza MJ, Adamas ME, Chalmers TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomised control trials. Psychological Medicine 1994;24:307-16.
107. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved antipsychotic. International Journal of Clinical Practise 2011;65(2):189-210.
108. Clarke M, Oxman AD (editors). Cochrane Reviewer's Handbook. Cochrane Database of Systematic Reviews 2002, issue 2.
109. Conley RR, Carpenter WT Jr, Tamminga CA. Time to clozapine response in a standardized trial. American Journal of Psychiatry 1997;154(9):1243-7.
110. Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie 1998;2 Suppl 43:25-40.
111. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives General Psychiatry 2003;60(6):553-64.
112. De Oliveira IR, De Sena EP, Pereira EL. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. Journal of Clinical Pharmacy and Therapeutics 1996;21(4):229-36.
113. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa. 2000.
114. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
115. Donner A, Klar N. Issues in the meta-analysis of cluster randomised trials. Statistics in Medicine 2002;21:2971-80.
116. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI:]
117. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
118. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: sulpiride versus placebo for schizophrenia 18/22 methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
119. Emsley R, McCreadie R, Livingston M, De Smedt G, Lemmens P. Risperidone in the treatment of first-episode schizophrenic patients with schizophreniform disorder: a double blind study. Congress of the International Academy for Biomedical and Drug Research on Critical Issues in the Treatment of Schizophrenia. 1995.
120. Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Archives of General Psychiatry 1978;35:837-44.
121. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172(13):1703-11.
122. Geddes J. Royal College of Psychiatrists guidelines on for the care of those with schizophrenia. The Schizophrenia Trials Meeting; 1999 May 5-7; Stratford-upon-Avon, UK 1999.
123. Glazer WM. Formulary decisions and health economics. Journal of Clinical Psychiatry 1998;59 Suppl 19:23-9.
124. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
125. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
126. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophrenia Bulletin 1997;23(4):567-82.
127. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
128. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
129. Hogarty GE, Goldberg SC. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Archives of General Psychiatry 1973;28(1):54-64.
130. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Archives of General Psychiatry 1974;31(5):603-8.
131. Hoyberg O, Fensbo C, Remvig J, LingJaerde O, Sloth-Neilsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica 1993;88:395-402.
132. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
133. Huttunen M, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel group trial. Acta Psychiatrica Scandinavica 1995;91:271-7.
134. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavanagh DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
135. Jadad A. Meta-analysis making the same mistakes as trials. Proceedings of the 2nd Symposium on Systematic Reviews: Beyond the Basics; 1999 Jan 5-7; Oxford, UK. 1999.
136. Johnson RE, McFarland BH. Antipsychotic drug exposure in a health maintenance organization. Medical Care 1993;31(5):432-44.
137. Joy C, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI:]
138. Kane JM. Schizophrenia. New England Journal of Medicine 1996;334(1):34-41.
139. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry 1996;153(7):948-50.
140. Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. American Journal of Psychiatry 1997;154(11):1525-9.
141. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from pet imaging. Molecular Psychiatry 1998;3(2):135-40.
142. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. American Journal of Psychiatry 2001;158(3):360-9.
143. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
144. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI:]
145. Kiivet RA, Llerena A, Dahl ML, Rootslane L, Sánchez Vega J, Eklundh T, et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. British Journal of Clinical Pharmacology 1995;40(5):467-76.
146. Kudo Y, Nomura J, Ikawa G, Nakajima T, Saito M, Sakai T, et al. Clinical trial of quetiapine in schizophrenia-efficacy and tolerability of quetiapine: a comparative double-blind study with mosapramine in schizophrenic patients. Proceeding of the Annual Meeting of the World Psychiatric Association; 1999 Aug; Hamburg, Germany. 1999.
147. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schizophrenia Research 1999;35:51-68.
148. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71.
149. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
150. Levy RH. Sedation in acute and chronic agitation. Pharmacotherapy 1996;6(Part 2):152-9S, 166-8S.
151. Lieberman J, Jody D, Geisler S. Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry 1993;50(5):369-76.
152. Marder SR. Facilitating compliance with antipsychotic medication. Journal of Clinical Psychiatry 1998;59(Suppl 3):21-5.
153. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
154. Miller R. Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1997;21(7):1059-94.
155. Milton GV, Jann MW. Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs. Clinical Pharmacokinetics 1995;28(6):494-504.
156. Murasaki M, Koyama T, Yamauchi T, Yagi MG, Ushijima S, Kamijima K. Clinical evaluation of quetiapine in schizophrenia-efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999.
157. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
158. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 1997;96:265-73.
159. Raschetti R, Spila Alegiani S, Diana G, Da Cas R, Traversa G, Pasquini P. Antipsychotic drug prescription in general practice in Italy. Acta Psychiatrica Scandinavica 1993;87(5):317-21.
160. Reardon GT, Rifkin A, Schwartz A, Myerson A, Siris SG. Changing patterns of neuroleptic dosage over a decade. American Journal of Psychiatry 1989;146(6):726-9.
161. Rosenheck MD, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003;290(20):2693-702.
162. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
163. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011:359-83.
164. Simpson M, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;212:11-9.
165. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI:]
166. Thornley B, Adams CE, Awad G. Chlorpromazine versus placebo for those with schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI:]
167. Thornley B, Adams CE. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317(7167):1181-4.
168. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
169. Whicher E, Morrison M, Douglas-Hall P. 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI:]
170. World Health Organization. WHO Model Lists of Essential Medicines, 2011 www.who.int/medicines/publications/essentialmedicines/en/. (accessed 20 June 2013).
171. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Medical Care 1999;37 Suppl 4:81-6.
172. Zito JM. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatric Clinics of North America 1998;21(1):181-202.
173. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
174. Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI:; PUBMED: 12137638]